Results 1 to 10 of about 168,928 (214)

Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment. [PDF]

open access: yesPLoS ONE, 2011
Murine monoclonal antibody V5B2 which specifically recognizes the pathogenic form of the prion protein represents a potentially valuable tool in diagnostics or therapy of prion diseases. As murine antibodies elicit immune response in human, only modified
Nives Skrlj   +4 more
doaj   +3 more sources

Novel humanized monoclonal antibodies against ROR1 for cancer therapy [PDF]

open access: yesMolecular Cancer
Background Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for
Rong Wei   +5 more
doaj   +2 more sources

A Review of Therapeutic Antibodies in Breast Cancer

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2021
Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer.
Maryam Eini   +4 more
doaj   +1 more source

Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease

open access: yesFrontiers in Allergy, 2023
IntroductionAllergic reactions are mediated by human IgE antibodies that bind to and cross-link allergen molecules. The sites on allergens that are recognized by IgE antibodies have been difficult to investigate because of the paucity of IgE antibodies ...
Bryan R. E. Smith   +11 more
doaj   +1 more source

Human monoclonal antibodies and monoclonal antibody multispecificity [PDF]

open access: yesBritish Journal of Cancer, 1987
The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and therefore are of limited value as blood borne agents.
AM Campbell, P Whitford, RE Leake
openaire   +2 more sources

Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model. [PDF]

open access: yesPLoS ONE, 2016
Clostridium difficile (C. difficile) infection (CDI) is the main cause of nosocomial antibiotic-associated colitis and increased incidence of community-associated diarrhea in industrialized countries.
Hongyu Qiu   +17 more
doaj   +1 more source

Antibody binding reports spatial heterogeneities in cell membrane organization [PDF]

open access: yes, 2022
The spatial organization of cell membrane glycoproteins and glycolipids is critical for mediating the binding of ligands, receptors, and macromolecules on the plasma membrane. However, we currently do not have the methods to quantify the spatial heterogeneities of macromolecular crowding on live cell surfaces.
arxiv   +1 more source

A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. [PDF]

open access: yesPLoS ONE, 2010
Rabbit antibodies have been widely used in research and diagnostics due to their high antigen specificity and affinity. Though these properties are also highly desirable for therapeutic applications, rabbit antibodies have remained untapped for human ...
Yanlan Yu   +13 more
doaj   +1 more source

New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?

open access: yesFrontiers in Immunology, 2022
Nephrotic proteinuria is the hallmark of several glomerulonephritis determined by different pathogenetic mechanisms, including autoimmune, degenerative and inflammatory.
Biswanath Basu   +5 more
doaj   +1 more source

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development [PDF]

open access: yes, 2017
Acknowledgments: The authors would like to acknowledge the funding support for this work from Scottish Enterprise [VNAR_001(2012)] and the Biotechnology and Biological Sciences Research Council (BB/K010905/1).Peer reviewedPublisher ...
Andrew J. Porter   +11 more
core   +6 more sources

Home - About - Disclaimer - Privacy